

Epclusa[®] (sofosbuvir/velpatasvir) Coadministration with Buprenorphine

This document is in response to your request for information regarding Epclusa[®] (sofosbuvir/velpatasvir [SOF/VEL]) and coadministration with buprenorphine.

Some data may be outside of the US FDA-approved Prescribing Information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.

PK DDI Evaluation

Drug interaction studies have not been conducted between the single-tablet regimen SOF/VEL and buprenorphine. Based on the PK profile of each active ingredient within SOF/VEL and buprenorphine, a PK interaction would not be predicted.^{1,2}

For more information about buprenorphine, please refer to its product labeling.²

SOF/VEL PK¹

DDI Mechanism		SOF	VEL
Drug Transporters	P-gp/BCRP	Substrate	Substrate/Inhibitor
	OATP1B1	N/A	Inhibitor
	OATP1B3	N/A	Inhibitor
	OATP2B1	N/A	Inhibitor
Drug Metabolizing Enzymes	CYP1A2	N/A	N/A
	CYP2B6	N/A	Substrate
	CYP2C8	N/A	Substrate
	CYP2C19/19	N/A	N/A
	CYP2D6	N/A	N/A
	CYP3A4	N/A	Substrate

Relevant SOF/VEL Label Information¹

There is no information in the SOF/VEL product labeling about the coadministration of SOF/VEL and buprenorphine.

Clearance of HCV infection with direct acting antivirals may lead to changes in hepatic function, which may impact safe and effective use of concomitant medications. Frequent monitoring of relevant laboratory parameters (INR or blood glucose) and dose adjustments of certain concomitant medications may be necessary. For more information, please refer to

Section 7.3 of the SOF/VEL US Prescribing Information (Established and Potentially Significant Drug Interactions).

Available Data

There are no Gilead studies evaluating the coadministration of SOF/VEL and buprenorphine. Medications commonly used for opioid substitution therapy (OST) were not excluded from pivotal phase 3 ASTRAL studies.³

Additionally, a literature search was conducted in Ovid MEDLINE and Embase databases for studies published between 1946 and February 26, 2026 using search terms that included Eplclusa, velpatasvir, sofosbuvir, buprenorphine, and related search terms.

Please find below a list of relevant citations assessing the impact of OST, including buprenorphine on the safety, efficacy, and adherence of SOF/VEL.

- Grebely, J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. *Lancet Gastroenterol Hepatol*. 2018;3(3): 153-161. [http://dx.doi.org/10.1016/S2468-1253\(17\)30404-1](http://dx.doi.org/10.1016/S2468-1253(17)30404-1).
- Cunningham EB, Amin J, Feld JJ, et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. *Int J Drug Policy*. 2018;62:14-23.
- Grebely J, Dore GJ, Zeuzem S, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. *Clin Infect Dis*. 2016;63(11): 1479-1481. <http://dx.doi.org/10.1093/cid/ciw579>
- Grebely J, Feld JJ, Wyles D, et al. Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: an analysis of phase 3 studies. *Open Forum Infect Dis*. 2018;5(2):ofy001. <http://dx.doi.org/10.1093/ofid/ofy001>
- Wilson J.W., Nestler S.R., Schaefer J.S., Holbrook E.A., Henderson H., McCoy B.K. Colocating Care: An Emergency Department-Based Medication for Opioid Use Disorder and Hepatitis C Virus Treatment Pathway. *Acad. Emerg. Med*. 2023;30(Supplement 1):381-382. doi:10.1111/acem.14718

If you require copies of this material be sent to you, please be aware that if you are a licensed US physician, this educational material is reportable under the Federal Open Payments/Sunshine Act. To obtain this material, please contact Gilead Medical Information at 866-Medi-GSI (866-633-4474) and refer to the case number.

References

1. Enclosed. Gilead Sciences Inc, EPCLUSA® (sofosbuvir and velpatasvir) tablets, for oral use. US Prescribing Information. Foster City, CA.
2. Indivior Inc., SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use CIII, North Chesterfield, VA.

Gilead Sciences, Inc. is providing this document to you, a US Healthcare Professional, in response to your unsolicited request for medical information.

3. Grebely J, Dore GJ, Zeuzem S, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis. 2016;63(11):1479-1481.

Abbreviations

BCRP=breast cancer
resistance protein
DDI=drug-drug interaction

OATP=organic anion
transporting polypeptide
P-gp=P-glycoprotein
PK=pharmacokinetic(s)

SOF=sofosbuvir
VEL=velpatasvir

Product Label

For the full indication, important safety information, and Boxed Warning(s), please refer to the Epclusa US Prescribing Information available at:

http://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Pharmacovigilance and Epidemiology ☎ 1-800-445-3235, option 3 or

🌐 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.

EPCLUSA, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2026 Gilead Sciences, Inc.